Fourteen percent of the world's people -- more than 800 million -- now have diabetes, a doubling of the global rate for the blood sugar disease since 1990, new statistics show.

Diabetes rates have doubled globally in the last three decades, a new study suggests, here’s what to know about the situation in Europe. View on euronews

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease, dyslipidaemia, hypertension, obstructive or sleep apnoea (OSA).

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results suggest that tirzepatide - the active ingredient in Lilly's diabetes drug Mounjaro and weight-loss treatment Zepbound - could prevent one new case of diabetes for every nine patients treated.